FibroGen, Inc (FGEN) Issues Quarterly Earnings Results
FibroGen, Inc (NASDAQ:FGEN) issued its earnings results on Monday. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.01, Morningstar.com reports. FibroGen had a negative return on equity of 36.41% and a negative net margin of 37.60%. The company had revenue of $29 million during the quarter, compared to the consensus estimate of $34.80 million.
Shares of FibroGen (FGEN) traded up 48.20% during trading on Tuesday, hitting $49.50. The company had a trading volume of 6,692,389 shares. FibroGen has a 52 week low of $15.60 and a 52 week high of $51.45. The stock’s market capitalization is $3.46 billion. The firm’s 50 day moving average is $32.84 and its 200-day moving average is $27.51.
Several research firms have weighed in on FGEN. Citigroup Inc. raised their price target on FibroGen to $65.00 and gave the company a “top pick” rating in a report on Tuesday. BidaskClub cut FibroGen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. William Blair reaffirmed an “outperform” rating on shares of FibroGen in a report on Monday, June 26th. Jefferies Group LLC began coverage on FibroGen in a report on Monday, July 10th. They issued a “buy” rating and a $50.00 price target on the stock. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $38.00 price target (up previously from $32.00) on shares of FibroGen in a report on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. FibroGen has an average rating of “Buy” and a consensus target price of $56.86.
In related news, insider K Peony Yu sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $33.48, for a total value of $334,800.00. Following the sale, the insider now directly owns 226,507 shares in the company, valued at $7,583,454.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Pat Cotroneo sold 28,346 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $33.97, for a total value of $962,913.62. Following the completion of the sale, the vice president now owns 170,666 shares in the company, valued at $5,797,524.02. The disclosure for this sale can be found here. Insiders sold 409,974 shares of company stock worth $12,647,338 over the last quarter. 14.90% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of FGEN. Acadian Asset Management LLC increased its stake in shares of FibroGen by 1,455.0% in the first quarter. Acadian Asset Management LLC now owns 148,490 shares of the biopharmaceutical company’s stock worth $3,661,000 after buying an additional 138,941 shares during the period. Principal Financial Group Inc. increased its stake in shares of FibroGen by 0.4% in the first quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock worth $3,354,000 after buying an additional 504 shares during the period. Sphera Funds Management LTD. increased its stake in shares of FibroGen by 6.4% in the first quarter. Sphera Funds Management LTD. now owns 165,700 shares of the biopharmaceutical company’s stock worth $4,085,000 after buying an additional 10,000 shares during the period. Teachers Advisors LLC increased its stake in shares of FibroGen by 1.4% in the first quarter. Teachers Advisors LLC now owns 468,413 shares of the biopharmaceutical company’s stock worth $11,546,000 after buying an additional 6,512 shares during the period. Finally, Parametric Portfolio Associates LLC bought a new stake in shares of FibroGen during the first quarter worth about $249,000. Institutional investors and hedge funds own 43.45% of the company’s stock.
FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.